| Customization: | Available |
|---|---|
| CAS No.: | 102518-79-6 |
| Formula: | C15h18n2o |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product Name: Daptomycin
CAS No.: 103060-53-3
Appearance: White powder
Specifications: USP-40; FDA-compliant
Description:
Daptomycin is a novel cyclic lipopeptide antibiotic derived from the fermentation of Streptomyces griseus subsp. xihuensis, a proprietary strain independently screened and optimized by our research team. It is a superantibiotic effective against multidrug-resistant Gram-positive bacteria, including strains resistant to vanco-mycin, methicillin, penicillin, and other antibiotics.
Key Technological Breakthroughs by Our Team:
Proprietary Strain Development:
Our team independently screened and identified Streptomyces griseus subsp. xihuensis, a strain with superior fermentation performance compared to the traditional Streptomyces reseosporus used globally.
Using advanced synthetic biology techniques, we comprehensively reconstructed the strain to achieve high-yield and stable production.
Optimized Fermentation and Purification Processes:
We redesigned the fermentation process to maximize productivity and consistency.
Through innovative purification techniques, we significantly reduced homologous impurities, achieving total impurities below 2%, fully compliant with FDA standards.
Purity and Quality Control:
Our advanced purification methods ensure the final product meets stringent quality requirements, with total impurities far below the industry average.
The product complies with USP-40 and FDA standards, ensuring global regulatory acceptance.
Intellectual Property and Innovation:
Our breakthroughs have resulted in multiple granted Chinese invention patents and a U.S. patent, demonstrating our independent intellectual property rights and technological leadership.
Key Features of Daptomycin:
Unique Mechanism of Action: Disrupts bacterial cell membrane function, rapidly killing Gram-positive bacteria.
Broad-Spectrum Efficacy: Effective against multidrug-resistant strains, including MRSA, VRE, and linezolid-resistant bacteria.
Critical Clinical Applications: Vital for treating life-threatening infections in critically ill patients.
Applications:
Treatment of complicated skin and soft tissue infections (cSSTI).
Management of bloodstream infections caused by Gram-positive bacteria.
Critical care for multidrug-resistant bacterial infections.
Packaging & Storage:
Sealed in moisture-proof containers under inert gas.
Store at 2-8°C, protected from light and humidity.
Note: Daptomycin was first discovered by Eli Lilly in the 1980s and later developed by Cubist Pharmaceuticals in 1997. Our team's technological advancements have significantly enhanced production efficiency, purity, and compliance with global regulatory standards.
For detailed specifications or regulatory documentation, please contact our team.
){kind=link}